OnCore Login

Return to Trial Database

HCRN-GI23-621

A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement

Status

Currently Enrolling

Cancer Type(s)

Liver and Bile Duct

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-GI23-621 being conducted in.
University of Alabama at Birmingham Comprehensive Cancer Center
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278